Brosche T, Platt D
Institute of Gerontology, University of Erlangen-Nürnberg, Germany.
Exp Gerontol. 1998 Aug;33(5):363-9. doi: 10.1016/s0531-5565(98)00014-x.
The phospholipid class of plasmalogens is ubiquitously found in considerable amounts as a constituent of mammalian cell membranes and of plasma lipoproteins. Plasmalogens are more susceptible to oxidative reactions compared to their fatty acid ester analogues, due to the reactivity of their enolether function. Studies on plasmalogen-deficient cell lines lead to the proposal that these ether lipids serve as endogenous antioxidants. No clear conclusions regarding the antioxidative effects of plasmalogens could be drawn from studies in patients of different ages with peroxisomal deficiency disorders. A defective peroxisomal plasmalogen synthesis is not necessarily associated with other defects in the metabolism of peroxisomes, as has been established in a cell line recently. In different mammalian tissues a decrease of plasmalogens with age was described. Moreover, an accumulation of plasmalogen oxidation products was measured in brain of old cattle compared to young ones. In pathologic conditions associated with oxidative stress like in spinal cord ischemia and reperfusion, plasmalogen levels varied inversely according to the oxidative burden. Oxidation products of plasmalogens increased with time of ischemia in infarcted porcine heart tissue. Enrichment of lipoproteins with plasmalogens increased their oxidative resistance, which was diminished in the case of LDL particles in patients with coronary arteriosclerosis. In red cell membranes plasmalogens were reduced with donor age and in hyperlipidemia. Under lipid lowering therapy with lovastatin an increase was observed, indicating a possible antioxidative impact of this treatment. Taken together, there is good evidence that plasmalogens are effective as endogenous antioxidants. However, more experimental approaches not confounded by other lipolytic processes are needed to establish this role of plasmalogens.
缩醛磷脂类磷脂作为哺乳动物细胞膜和血浆脂蛋白的组成成分,在体内广泛存在且含量可观。与脂肪酸酯类似物相比,缩醛磷脂更容易发生氧化反应,这是由于其烯醚功能具有较高的反应活性。对缺乏缩醛磷脂的细胞系进行的研究表明,这些醚脂可作为内源性抗氧化剂。在患有过氧化物酶体缺乏症的不同年龄段患者中开展的研究,未能就缩醛磷脂的抗氧化作用得出明确结论。最近在一个细胞系中证实,过氧化物酶体缩醛磷脂合成缺陷并不一定与过氧化物酶体代谢的其他缺陷相关。在不同的哺乳动物组织中,均发现缩醛磷脂含量会随年龄增长而降低。此外,与幼年牛相比,老年牛大脑中缩醛磷脂氧化产物有所积累。在与氧化应激相关的病理状况下,如脊髓缺血和再灌注时,缩醛磷脂水平与氧化负荷呈负相关。在梗死的猪心脏组织中,缩醛磷脂的氧化产物随缺血时间增加。用缩醛磷脂富集脂蛋白可增强其抗氧化能力,而在冠状动脉粥样硬化患者的低密度脂蛋白颗粒中,这种能力则会减弱。在红细胞膜中,缩醛磷脂含量会随献血者年龄增长及高脂血症而降低。在使用洛伐他汀进行降脂治疗时,缩醛磷脂含量会升高,这表明该治疗可能具有抗氧化作用。综上所述,有充分证据表明缩醛磷脂可作为有效的内源性抗氧化剂。然而,需要更多不受其他脂解过程干扰的实验方法来确定缩醛磷脂的这一作用。